FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004657369> ?p ?o ?g. }

• W2004657369 endingPage "158" @default.
• W2004657369 startingPage "151" @default.
• W2004657369 abstract "A sulfonylurea--usually glyburide--plus metformin constitute the most widely used oral antihyperglycemic combination in clinical practice. Both medications present undesirable cardiovascular effects. The issue whether the adverse effects of each of these pharmacologic agents may be additive and detrimental to the prognosis for coronary patients has not yet been specifically addressed.This study was designed to examine the survival in type 2 diabetics with proven coronary artery disease (CAD) receiving a combined glyburide/metformin antihyperglycemic treatment over a long-term follow-up period.The study sample comprised 2,275 diabetic patients, aged 45-74 years, with proven CAD, who were screened but not included in the bezafibrate infarction prevention study. In addition, 9,047 nondiabetic patients with CAD represented a reference group. Diabetics were divided into four groups on the basis of their therapeutic regimen: diet alone (n = 990), glyburide (n = 953), metformin (n = 79), and a combination of the latter two (n = 253).The diabetic groups presented similar clinical characteristics upon recruitment. Crude mortality rate after a 7.7-year follow-up was lower in nondiabetics (14 vs. 31.6%, p<0.001). Among diabetics, 720 patients died: 260 on diet (mortality 26.3%), 324 on glyburide (34%), 25 on metformin alone (31.6%), and 111 patients (43.9%) on combined treatment (p<0.000001). Time-related mortality was almost equal for patients on metformin and on combined therapy over an intermediate follow-up period of 4 years (survival rates 0.80 and 0.79, respectively). The group on combined treatment presented the worst prognosis over the long-term follow-up, with a time-related survival rate of 0.59 after 7 years, versus 0.68 and 0.70 for glyburide and metformin, respectively. After adjustment to variables for prognosis, the use of the combined treatment was associated with an increased hazard ratio (HR) for all-cause mortality of 1.53 (95% confidence interval [CI] 1.20-1.96), whereas glyburide and metformin alone yielded HR 1.22 (95% CI 1.02-1.45) and HR 1.26 (95% CI 0.81-1.96), respectively.We conclude that after a 7.7-year follow-up, monotherapy with either glyburide or metformin in diabetic patients with CAD yielded a similar outcome and was associated with a modest increase in mortality. However, time-related mortality was markedly increased when a combined glyburide/metformin treatment was used." @default.
• W2004657369 created "2016-06-24" @default.
• W2004657369 creator A5004886183 @default.
• W2004657369 creator A5011207334 @default.
• W2004657369 creator A5012270561 @default.
• W2004657369 creator A5028734680 @default.
• W2004657369 creator A5046330272 @default.
• W2004657369 creator A5056244803 @default.
• W2004657369 creator A5066402379 @default.
• W2004657369 creator A5067030113 @default.
• W2004657369 creator A5067683880 @default.
• W2004657369 creator A5084494904 @default.
• W2004657369 creator A5085751450 @default.
• W2004657369 date "2001-02-01" @default.
• W2004657369 modified "2023-10-14" @default.
• W2004657369 title "Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up" @default.
• W2004657369 cites W1963659285 @default.
• W2004657369 cites W1967943195 @default.
• W2004657369 cites W1972025106 @default.
• W2004657369 cites W1973331125 @default.
• W2004657369 cites W1974947331 @default.
• W2004657369 cites W1977349752 @default.
• W2004657369 cites W1982271467 @default.
• W2004657369 cites W1990490378 @default.
• W2004657369 cites W2018715171 @default.
• W2004657369 cites W2030326519 @default.
• W2004657369 cites W2032354327 @default.
• W2004657369 cites W2037145603 @default.
• W2004657369 cites W2040421307 @default.
• W2004657369 cites W2054819931 @default.
• W2004657369 cites W2055473110 @default.
• W2004657369 cites W2060209571 @default.
• W2004657369 cites W2065949317 @default.
• W2004657369 cites W2069359070 @default.
• W2004657369 cites W2071723829 @default.
• W2004657369 cites W2075378374 @default.
• W2004657369 cites W2078482750 @default.
• W2004657369 cites W2078543127 @default.
• W2004657369 cites W2085361695 @default.
• W2004657369 cites W2143889573 @default.
• W2004657369 cites W2153475498 @default.
• W2004657369 cites W2162891101 @default.
• W2004657369 cites W2188846692 @default.
• W2004657369 cites W2271771390 @default.
• W2004657369 cites W2302447233 @default.
• W2004657369 cites W2312968642 @default.
• W2004657369 cites W2317172136 @default.
• W2004657369 cites W2324992560 @default.
• W2004657369 cites W2337454357 @default.
• W2004657369 cites W2769264260 @default.
• W2004657369 cites W2786617581 @default.
• W2004657369 cites W3119011082 @default.
• W2004657369 cites W4242344507 @default.
• W2004657369 cites W4298211110 @default.
• W2004657369 cites W47644979 @default.
• W2004657369 cites W73759183 @default.
• W2004657369 doi "https://doi.org/10.1002/clc.4960240210" @default.
• W2004657369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6655246" @default.
• W2004657369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11460818" @default.
• W2004657369 hasPublicationYear "2001" @default.
• W2004657369 type Work @default.
• W2004657369 sameAs 2004657369 @default.
• W2004657369 citedByCount "94" @default.
• W2004657369 countsByYear W20046573692012 @default.
• W2004657369 countsByYear W20046573692013 @default.
• W2004657369 countsByYear W20046573692014 @default.
• W2004657369 countsByYear W20046573692015 @default.
• W2004657369 countsByYear W20046573692016 @default.
• W2004657369 countsByYear W20046573692017 @default.
• W2004657369 countsByYear W20046573692018 @default.
• W2004657369 countsByYear W20046573692021 @default.
• W2004657369 countsByYear W20046573692022 @default.
• W2004657369 crossrefType "journal-article" @default.
• W2004657369 hasAuthorship W2004657369A5004886183 @default.
• W2004657369 hasAuthorship W2004657369A5011207334 @default.
• W2004657369 hasAuthorship W2004657369A5012270561 @default.
• W2004657369 hasAuthorship W2004657369A5028734680 @default.
• W2004657369 hasAuthorship W2004657369A5046330272 @default.
• W2004657369 hasAuthorship W2004657369A5056244803 @default.
• W2004657369 hasAuthorship W2004657369A5066402379 @default.
• W2004657369 hasAuthorship W2004657369A5067030113 @default.
• W2004657369 hasAuthorship W2004657369A5067683880 @default.
• W2004657369 hasAuthorship W2004657369A5084494904 @default.
• W2004657369 hasAuthorship W2004657369A5085751450 @default.
• W2004657369 hasBestOaLocation W20046573692 @default.
• W2004657369 hasConcept C126322002 @default.
• W2004657369 hasConcept C134018914 @default.
• W2004657369 hasConcept C179755657 @default.
• W2004657369 hasConcept C2776999253 @default.
• W2004657369 hasConcept C2777180221 @default.
• W2004657369 hasConcept C2777448766 @default.
• W2004657369 hasConcept C2778213512 @default.
• W2004657369 hasConcept C2778854520 @default.
• W2004657369 hasConcept C2779306644 @default.
• W2004657369 hasConcept C2779768347 @default.
• W2004657369 hasConcept C2780323712 @default.
• W2004657369 hasConcept C2781413609 @default.
• W2004657369 hasConcept C500558357 @default.

• next